Co-Diagnostics to show new PCR platform at Munich infection meeting

Company to engage with global customers and distributors while expanding international commercial relationships

, /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will participate in the Congress of the European Society of Clinical Microbiology and Infectious Disease (“ESCMID Global”) 2026, taking place April 17-21 in Munich, Germany.

ESCMID Global 2026 features academic and industry programming that brings together clinical microbiology and infectious diseases leaders dedicated to advancing scientific, education, research and state-of-the-art technologies. Prior ESCMID Global events have historically attracted more than 16,000 registrants, nearly a third of which originated from outside of Europe, underscoring its role as the premier global forum for the infectious disease community.

Company representatives look forward to establishing and strengthening relationships with new and existing customers and distributors from around the world while also showcasing the Company’s suite of CE-IVD testing solutions for clinical laboratories, as well as the upcoming Co-Dx PCR platform*.

Registrants interested in learning more about Co-Diagnostics are invited to visit Booth #G55.

*The Co-Dx PCR platform (including the PCR Home^®, PCR Pro^®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-to-showcase-co-dx-pcr-platform-and-ce-ivd-solutions-at-escmid-2026-in-munich-germany-302741220.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) present at ESCMID Global 2026 in Munich?

Co-Diagnostics will participate April 17-21, 2026 at ESCMID Global in Munich. According to Co-Diagnostics, company staff will engage global customers and distributors at Booth #G55 to showcase CE-IVD testing solutions and the Co-Dx PCR platform.

What will Co-Diagnostics (CODX) showcase at ESCMID Global 2026?

Co-Diagnostics will showcase its CE-IVD testing solutions and the upcoming Co-Dx PCR platform. According to Co-Diagnostics, demonstrations include the suite of CE-IVD tests and information about PCR Home, PCR Pro, and companion mobile app.

Is the Co-Dx PCR platform available for sale at ESCMID Global 2026 (CODX)?

No, the Co-Dx PCR platform is not yet for sale and remains under regulatory review. According to Co-Diagnostics, the platform and associated tests are subject to FDA and other regulatory reviews before commercial availability.

Where can attendees find Co-Diagnostics (CODX) at ESCMID Global 2026?

Attendees can visit Co-Diagnostics at Booth #G55 during the April 17-21 event in Munich. According to Co-Diagnostics, company representatives will be available to discuss CE-IVD products and international distribution opportunities.

How will Co-Diagnostics (CODX) use ESCMID Global 2026 to expand internationally?

Co-Diagnostics aims to establish and strengthen distributor and customer relationships at the Congress. According to Co-Diagnostics, engagement with registrants from over 16,000 past attendees will support international commercial development and product awareness.